COMMUNIQUÉS West-GlobeNewswire

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
16/04/2026
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up [...]
Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
16/04/2026
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑ [...]
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
16/04/2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex virus infections, with [...]
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
16/04/2026
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First ‑ in ‑ class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation CAMBRIDGE, [...]
CancerVax to Target Colorectal Cancer Following Recent Biodistribution Breakthroughs
16/04/2026
New findings support hypothesis that current nanoparticle designed for pancreatic and liver cancers could also work for colorectal cancer Lehi, Utah, April 16, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of [...]
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12
16/04/2026
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12 Berlin, Allemagne, le 16 avril 2026, 8 h 00 [...]
Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine
16/04/2026
COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA ® (recombinant, adsorbed) for active immunization [...]
Pharming Group announces the 2026 Annual General Meeting of Shareholders
16/04/2026
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “ [...]
Eurobio Scientific signe un accord définitif en vue de l'acquisition de la division « Lab Products » de CareDx dédiée à la transplantation
16/04/2026
EUROBIO SCIENTIFIC SIGNE UN ACCORD DÉFINITIF EN VUE DE L'ACQUISITION DE LA DIVISION « LAB PRODUCTS 1 » DE CAREDX DÉDIÉE À LA TRANSPLANTATION L'acquisition du portefeuille « Lab Products » de CareDx ouvre de nouvelles [...]
Greywolf Therapeutics appoints Edwin Moses as Chair
16/04/2026
OXFORD, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin [...]
ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase
16/04/2026
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications
16/04/2026
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany , April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth [...]
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
16/04/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) -- BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or [...]
Eurobio scientific signs definitive agreement to acquire CareDx’s transplant Lab Product division
16/04/2026
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing [...]
UroFlow Claims Evaluated: Reviewing the Official Website Benefits & Ingredients to Support Prostate Health
16/04/2026
A 2026 consumer information overview of how UroFlow presents its Saw Palmetto, Pygeum Africanum, Lycopene, and Tomato Sauce Trick ingredient references, official website benefit descriptions, pricing structure, and [...]
Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation
15/04/2026
VANCOUVER, British Columbia, April 15, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “ Company ” or “ Algernon ”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that effective [...]
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
15/04/2026
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity, Ratutrelvir topline Phase 2a data show a differentiated [...]
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
15/04/2026
Expanded treatment in community settings will reduce patient burden Option to redose patients granted in both Ntrust-1 and Ntrust-2 studies Rheumatoid arthritis cohort to be added to Ntrust-2 Dosing continues at 4 [...]
Wave Life Sciences Announces Proposed Redomiciliation to the United States
15/04/2026
CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]

Pages